Peddock Capital Advisors’s Seres Therapeutics MCRB Stock Holding History

Peddock Capital Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-99	Closed	-$48K	–	234
2020 Q4	$48K	Buy	+99	New	+$58K	0.03%	168
2020 Q1	–	Sell	-165	Closed	-$11K	–	182
2019 Q4	$11K	Buy	+165	New	+$12.2K	0.01%	217
2019 Q2	–	Sell	-15	Closed	-$2K	–	180
2019 Q1	$2K	Hold	15	–	–	﹤0.01%	243
2018 Q4	$1K	Hold	15	–	–	﹤0.01%	252
2018 Q3	$2K	Hold	15	–	–	﹤0.01%	253
2018 Q2	$3K	Hold	15	–	–	﹤0.01%	245
2018 Q1	$2K	Hold	15	–	–	﹤0.01%	245
2017 Q4	$3K	Hold	15	–	–	﹤0.01%	237
2017 Q3	$5K	Hold	15	–	–	﹤0.01%	229
2017 Q2	$3K	Hold	15	–	–	﹤0.01%	234
2017 Q1	$3K	Hold	15	–	–	﹤0.01%	214
2016 Q4	$3K	Hold	15	–	–	﹤0.01%	203
2016 Q3	$4K	Buy	+15	New	+$5.26K	﹤0.01%	216

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Peddock Capital Advisors's MCRB Position: Q1 2021 in Review

Peddock Capital Advisors sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 99 shares — an estimated $48K sold.

Peddock Capital Advisors first reported a position in MCRB in Q3 2016 and held it in 13 quarters. The position peaked at $48K in Q4 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

Peddock Capital Advisors reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
Peddock Capital Advisors sold 99 Seres Therapeutics shares in Q1 2021, an estimated $48K.
Peddock Capital Advisors first reported a position in Seres Therapeutics in Q3 2016 and held it in 13 quarters.
Peddock Capital Advisors's Seres Therapeutics position peaked at $48K in Q4 2020.
152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on Peddock Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.